Literature DB >> 6126491

Hidradenitis suppurativa: evidence for a bactericidal defect correctable by cholinergic agonist in vitro and in vivo.

P A Ginder, M Ousley, D Hinthorn, C Liu, N I Abdou.   

Abstract

Hidradenitis suppurativa (HS) affects the apocrine sweat glands, giving chronic recurrent abscesses of axillary and perineal areas. We report a patient who had a defect in polymorphonuclear leukocyte killing of bacteria associated with low levels of intracellular cyclic GMP. This defect was corrected with a cholinergic agonist in vitro. Treatment of the patient with a cholinergic agonist, bethanechol chloride, resulted in prolonged clinical improvement, normal bactericidal function, and normal levels of intracellular cyclic GMP. The possible mechanisms responsible for the bactericidal defect and for the patient's improvement are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126491     DOI: 10.1007/bf00915227

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  15 in total

1.  Malakoplakia: evidence for monocyte lysosomal abnormality correctable by cholinergic agonist in vitro and in vivo.

Authors:  N I Abdou; C NaPombejara; A Sagawa; C Ragland; D J Stechschulte; U Nilsson; W Gourley; I Watanabe; N J Lindsey; M S Allen
Journal:  N Engl J Med       Date:  1977-12-29       Impact factor: 91.245

2.  Oxygen-dependent microbial killing by phagocytes (first of two parts).

Authors:  B M Babior
Journal:  N Engl J Med       Date:  1978-03-23       Impact factor: 91.245

3.  Relationship of immunoglobulin to complement receptors of human B cells.

Authors:  I Abrahamsohn; U R Nilsson; N I Abdou
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

4.  Correction of characteristic abnormalities of microtubule function and granule morphology in Chediak-Higashi syndrome with cholinergic agonists.

Authors:  J M Oliver; R B Zurier
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

5.  Effect of Mycobacterium leprae on lymphocyte proliferation: suppression of mitogen and antigen responses of human peripheral blood mononuclear cells.

Authors:  J Touw; G L Stoner; A Belehu
Journal:  Clin Exp Immunol       Date:  1980-09       Impact factor: 4.330

6.  Mycobacterium fortuitum infection: evidence of bactericidal defect due to hyperactive antigen-specific suppressor cells. Correction in vitro and in vivo by cholinergic agonist and indomethacin.

Authors:  J D Gardner; M Ousley; W Godfrey; N J Lindsey; N I Abdou
Journal:  Am J Med       Date:  1982-11       Impact factor: 4.965

Review 7.  Impaired microtubule function correctable by cyclic GMP and cholinergic agonists in the Chediak-Higashi syndrome.

Authors:  J M Oliver
Journal:  Am J Pathol       Date:  1976-11       Impact factor: 4.307

8.  Improvement of Chediak-Higashi leukocyte function by cyclic guanosine monophosphate.

Authors:  L A Boxer; M Rister; J M Allen; R L Baehner
Journal:  Blood       Date:  1977-01       Impact factor: 22.113

9.  Fibroblasts and macrophages of mice with the Chediak-Higashi-like syndrome have microtubules and actin cables.

Authors:  F R Frankel; R W Tucker; J Bruce; R Stenberg
Journal:  J Cell Biol       Date:  1978-11       Impact factor: 10.539

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  3 in total

1.  Comorbidities of hidradenitis suppurativa (acne inversa).

Authors:  Sabine Fimmel; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2010-01

Review 2.  Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.

Authors:  Namrita Halder; Girdhari Lal
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

3.  Cyclosporin-responsive hidradenitis suppurativa.

Authors:  D A Buckley; S Rogers
Journal:  J R Soc Med       Date:  1995-05       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.